Journal for ImmunoTherapy of Cancer. 2025; 13(8); e010465Temporal optimization of CD25-biased IL-2 agonists and immune checkpoint blockade leads to synergistic anticancer activity despite robust regulatory T cell expansion Kilic I.Weberová P.VanDyke D.Šírová M.Kubešová K.Fabilane C.Mazhara V.Liu K.Běhalová K.Ptáček B.Říhová B.Spangler J.Kovář M.Zobrazit další (8) 10.1136/jitc-2024-010465
